Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Non-comparative Phase II Multicentric Trial on Short Term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer

NCT05346848 is registered in ClinicalTrials.gov with Institut Bergonié as lead sponsor.

NCT NCT05346848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05346848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Non-comparative Phase II Multicentric Trial on Short Term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer
Lead sponsor
Institut Bergonié
Phase
Phase 2
Overall status
Recruiting
Start date
February 24, 2023
Completion date
February 28, 2030
Enrollment
62 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer